The aim of this study was to reduce the rate of graft failure after HLA non-identical stem cell transplantation by using G-CSF mobilized CD34
may also be improved by increasing the number of grafted cells, either using unmanipulated bone marrow, taking advantage of the effect of alloreactive T cells or, as shown in recent studies, by using high numbers of highly purified T cell-depleted stem cells. 9 The latter approach was used by Aversa et al to transplant patients with leukemia from HLA non-identical family donors using either a combination of purified peripheral blood progenitor cells (PBPC) and T cell-depleted marrow or, in more recent patients, PBPC alone. [10] [11] [12] A remarkably high engraftment rate of more than 90% was observed.
Here we report results of a pilot study in pediatric patients, where we explored a comparable transplant approach. Like the findings of Aversa et al, we observed a high engraftment rate of 86%. In contrast, GVHD developed in the initial patients, but was completely preventable in patients receiving grafts containing fewer T cells than 5 ϫ 10 4 /kg.
Patients and methods

Patients
Twenty-three pediatric patients, ranging in age from 2 months to 18 years, were included in the study, which had been approved by the local ethics committee. Informed consent by the patient and/or the parents was obtained. In Table 1 , details of the underlying disorders, the donors and the conditioning regimen used are presented. Fourteen patients had advanced leukemia and nine patients suffered from congenital hematological or immunological disorders which were life-threatening and without alternative treatment options. Donors were with two exceptions parents, in one an uncle and in another a brother. HLA disparities were in one case 1 locus involving MHC class II, in nine cases 2 loci and in 13 cases 3 loci. Conditioning was not uniform. Patients with malignancies usually received total body irradiation (TBI), which was given over 3 days in six fractions at a total dose of 12 Gy on days −8 to −6. In the others busulphan was used, in infants at 5 mg/kg/day, in the others at 4 mg/kg/day on 4 consecutive days (days −11 to −8). All patients received thiotepa, in patients with TBI usually at 20 mg/kg (day −5 and −4) and in patients with busulphan at 10 mg/kg (day −7). Cyclophosphamide was given at total doses of 120 mg/kg in patients with TBI (days −3 and −2) and at 200 mg/kg in the others (days −6 to −3) except in three cases, where 576 cyclophosphamide was reduced to 120 mg/kg (UPN 292, 293 and 294). All patients received rabbit anti-human lymphocyte globulin (ALG, Lymphoglobulin, Pasteur-Merieux, Leimen, Germany) on 3 or 4 consecutive days at total doses of 30 to 40 mg/kg, starting usually on day −4 prior to transplantation. Beside T cell depletion no further GVHD prophylaxis was used. All patients received standard oral antimicrobial prophylaxis and in addition i.v. antibiotics during aplasia. Patients at high risk for fungal infection received three weekly doses of i.v. amphotericin B. Immunoglobulins were substituted to keep IgG levels Ͼ7 g/l during the first 6 months after transplantation. No regular treatment with G-CSF to accelerate neutrophil reconstitution was used.
Graft processing
Bone marrow was harvested from donors prior to G-CSF treatment and was depleted of T cells by lectin agglutination and E-rosetting using donor red blood cells coated with complexes of CD2 and CD3 antibodies (CLB, Amsterdam, The Netherlands). 13 In order to mobilize CD34 + PBPC, donors were injected subcutaneously with rHuG-CSF (Lenogastrim, Rhône-Poulenc, Cologne, Germany) at doses of 10 to 20 g/kg/day. Leukapheresis was performed on day 4 and day 5 of treatment, using the COBE Spectra Cell Separator (COBE BCT, Heimstetten, Germany). The first leukapheresis product was usually stored overnight at 4°C and processed the next day, together with the second leukapheresis product. CD34 + cells were purified by positive selection, using the CeprateSC device (CellPro, Brussels, Belgium), and further depleted of T cells by E-rosetting as described. 14, 15 Enumeration of CD34-positive cells and of CD3-positive cells was performed by flow cytometry using the following antibodies: CD34-PE, CD3-PE (Becton-Dickinson, Heidelberg, Germany), CD45-FITC, CD2-FITC, CD3-PE (Dako, Hamburg, Germany) and CD2-FITC, CD3-FITC (Immunotech, Krefeld, Germany).
All donors had given informed consent to treatment by G-CSF and to undergoing leukapheresis according to a study protocol approved by the local ethics committee.
Results
Processing of transplants
After lectin-agglutination and E-rosetting of bone marrow, the median recovery of CD34 + cells was 42% (15-71%) and T cell depletion was 2.9 log (2.3 log-4.6 log) (unless otherwise stated, numbers indicate median and range). The recovery of CD34 + cells from leukapheresis products following positive selection was 83% (44-100%). Following further T cell depletion by E-rosetting, the overall recovery of CD34
+ cells was 68% (32-83%) and a 5.2 log T cell depletion (4.2-6.2 log) was achieved. The total numbers of CD34 + cells transplanted in each patient, as well as the residual T cells contained in the grafts, are shown in Table 2 .
Engraftment
Two patients could not be analyzed for engraftment because of early death (UPN 219 and 242) . Eighteen of the other 21 patients developed sustained engraftment as defined by neutrophil counts Ͼ0.4 × 10 9 /l on 3 consecutive days. Neutrophil counts in these cases started to rise during the second or third week after transplantation and reached Ͼ0.5 × 10 9 /l on day +17 (day +9 to +43) and Ͼ1.0 × 10 9 /l on day +22 (day +10 to +54). Independence from platelet transfusions was attained on day +21 (day +4 to +45). We observed no correlation between the total number of grafted CD34 + cells and the duration of aplasia or the kinetics of hematological recovery. There was no difference with regard to these parameters between patients receiving PBPC only or a combination of bone marrow and PBPC.
Four patients developed graft failure. In patient UPN 253 a functioning graft was lost on day +28. This patient had developed CMV infection and was treated with gancyclovir at the time of graft failure. He received a second transplant from his HLA haplo-identical brother following reconditioning with cyclophosphamide at 120 mg/kg and ALG and subsequently showed sustained engraftment. The three other patients with graft failure (UPN 292, 293 and 294) had received conditioning with chemotherapy, using cyclophosphamide at the reduced dose of 120 mg/kg in an attempt to limit toxicity. Second transplants in these patients from the other parent following reconditioning with two doses of cyclophosphamide and repeated ALG were unsuccessful and two of these patients died in aplasia, while one patient with Wiskott-Aldrich syndrome slowly recovered autologous hematopoiesis and survives at present receiving regular platelet and red cell transfusions.
GVHD
Of 18 patients with stable engraftment (including UPN 253 after retransplantation), five patients developed grade II to III acute GVHD while 13 patients remained free of this complication. GVHD involved the skin and in two patients also the intestinal tract. The average day of onset of GVHD was day +17 (day +11 to +34). GVHD in all five cases responded incompletely to steroid treatment, requiring the prolonged use of immunosuppressive treatment. All patients with GVHD had received combined grafts of bone marrow and PBPC containing residual T cell numbers ranging from 8 to 20 ϫ the Wilcoxon-Mann-Whitney exact test gave a P value of 0.0002 for the median of grafted T cells in the two groups of patients.
Immunological reconstitution
Immunological reconstitution in eight evaluable patients without GVHD was characterized by the predominance of NK cells during the first 3 months. CD3 + cells started to rise between the 3rd and 4th month (Figure 2 ). T cell reconstitution showed a simultaneous appearance of CD4 + and CD8
+ cells with a predominance of CD4 + cells (Figure 3 ). Functional analysis revealed normal proliferative responses upon stimulation with PHA (defined as stimulatory index Ͼ100) between day +106 and +164 (median day +133) and positive antigen specific proliferation as measured in the mixed lymphocyte reaction (stimulatory index Ͼ10) between day +107 and +293 (median day +133).
Survival and complications
Of 23 patients, nine are currently alive after successful transplantation with a median survival time of 183 days. In 12 evaluable patients with leukemia, four are currently surviving in remission. No early relapses were observed in five patients who developed GVHD, while of seven evaluable patients without GVHD, two died from early relapse. The major cause of death in patients with GVHD were infectious complications.
Of nine patients with non-malignant disorders, two died from complications of graft failure, one from EBV-LPS and one from respiratory failure due to pulmonary hypertension. The other five patients are currently alive and in good clinical condition with stable hematological functions and without further treatment (Table 2) .
Discussion
In this study we confirm recent data published by Aversa et al 10, 12 showing that the use of large numbers of T cell-depleted CD34 + PBPC from HLA-haploidentical donors, either in combination with marrow or as the only grafts, markedly improved engraftment as compared to previous experience of HLA non-identical BMT. This prevention of graft failure may be due to several factors. One major factor is the relatively high number of CD34 + cells. Additional biological features of PBPC may contribute to their higher engraftment potential. As reported by several groups, the large majority of PBPC are in a quiescent, non-cycling status, as compared to marrow progenitor cells. [16] [17] [18] [19] In mice it has been demonstrated that cycling and noncycling progenitor cells differ with regard to their potential to home into the marrow, which is higher in noncycling cells as compared to the cycling population. 20 Also a higher expression by PBPC of adhesion molecules, as compared to stem cells isolated from marrow, may be responsible for the observed high engraftment potential. [21] [22] [23] The improvement of engraftment after PBPC transplantation may thus be related not only to a quantitative but also to a qualitative advantage of these progenitor cells as compared to marrow cells. In addition, recent in vitro studies showed that highly purified CD34
+ PBPC may have a tolerizing effect on T cells, suggesting another possible mechanism for the observed low rate of graft rejection. 24 The intensified conditioning used in the present study may also be pivotal for the low rate of graft failure. Thiotepa and ALG were added to a standard regimen of TBI and cyclophosphamide or busulphan and cyclophosphamide. While the reduction of thiotepa from 20 to 10 mg/kg did not impair engraftment in our study, reduction of cyclophosphamide from 200 mg/kg to 120 mg/kg, when used in combination with busulphan, increased the risk of graft failure.
In our opinion the relative contribution of the intensified conditioning, the high number as well as additional biological features of PBPC for improvement of the engraftment rate still remains undefined. There is no larger control group of patients transplanted with marrow only, using the same intensified conditioning. In fact, our group demonstrated stable engraftment in a small series of three patients with Wiskott-Aldrich syndrome, who received the same intensive conditioning regimen and marrow grafts from HLA non-identical parents. 25 An important finding in the present study, which involved only pediatric patients, was the requirement of grafts with an extremely low residual T cell load for complete prevention of GVHD. /kg without developing significant GVHD. In the more recent study from the same group, patients were grafted with a mean of 3.5 ϫ 10 4 CD3 + cells (a maximum of 7.7 ϫ 10 4 /kg CD3 + cells) with complete prevention of GVHD. 12 Based on these studies, the critical threshold to prevent GVHD after HLA haplo-identical transplantation appears to be 5 ϫ 10 4 /kg. In our patients the combined use of marrow and PBPC failed to reach this threshold in seven of nine cases, mainly due to T cells supplied from bone marrow grafts. With improved T cell depletion of the marrow, GVHD was completely preventable.
The high purity of CD34 + cells in PBPC transplants facilitates direct quantification of residual T cells. Kernan et al 26 have previously published a study in the HLA-identical transplant setting, where residual T cells were determined by limiting dilution. These authors could demonstrate that patients receiving less than 1 ϫ 10 5 clonable T cells/kg remained free of GVHD. The critical T cell number in HLA-identical and HLA non-identical donor transplants thus does not appear to differ as markedly as one may expect, although this may be due to the different methods used to evaluate the T cell content. In addition the use of ALG as immunosuppression might contribute to further in vivo T cell depletion. One case reported in the study by Aversa et al, 12 who developed GVHD grade IV after secondary infusion of 3 ϫ 10 4 /kg donor T cells would support this suggestion. Our limited experience of secondary unmanipulated donor T cell infusions does not however confirm this reported complication, since transfer of HLA non-identical unmanipulated donor T cells was found to be safe as long as given in numbers below 5 ϫ 10 4 /kg (unpublished observation).
The pattern of immunologic reconstitution in eight patients without GVHD was initially characterized by a dominance of donor NK cells. The appearance of mature functioning T cells, predominantly CD4 + cells, was delayed for 3 to 4 months and was followed by rapid normalization of T cell immunity. Subsequent studies demonstrated stable and complete T cell reconstitution. This delayed pattern of immune reconstitution is similarly observed in patients with primary immunodeficiencies, transplanted with T celldepleted HLA non-identical bone marrow, likely reflecting the time of thymus-dependent maturation of T cells from precursor cells. 27, 28 In a group of adult patients, Albi et al 29 reported a similar rapid reconstitution of NK cells after HLA non-identical transplantation. T cell reconstitution however was more heterogenous and was dominated by the appearance of CD8 + cells. This difference in immunologic reconstitution might be due to age-related alterations in thymus function: although allowing maturation, the output of T cells in the adult thymus clearly seems to be impaired as recently demonstrated. 30 It is evident that transplantation of highly purified PBPC from HLA non-identical donors alone can lead to sustained hematological and immunological reconstitution. At present it remains open whether PBPC are capable of providing long-term reconstitution. Since the content of true progenitor cells in these grafts is currently poorly defined, delayed exhaustion of hematopoietic functions can not be excluded. However experiences in HLA-identical PBPC transplants do not provide any indication for this possibility. 31, 32 In our study, complications from infections like CMV and EBV were observed predominantly in patients receiving immunosuppressive therapy for treatment of GVHD, whereas the majority of patients without GVHD had a surprisingly uncomplicated course. The delayed immunologic reconstitution is thus not necessarily associated with increased infectious complications.
With regard to the risk of leukemic relapse after HLA non-identical PBPC transplantation no firm conclusions can be drawn from our small series of patients. Although complete prevention of GVHD may limit a potential GVL effect in these transplants, a residual antileukemic activity may nevertheless be achieved by the low number of grafted HLA non-identical donor T cells.
